Your session is about to expire
← Back to Search
LP-300 + Chemotherapy for Lung Adenocarcinoma (HARMONIC Trial)
HARMONIC Trial Summary
This trial is testing a new cancer drug combo to see if it's more effective than the current standard of care, in patients who have never smoked.
HARMONIC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:HARMONIC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HARMONIC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never smoked.My lung cancer cannot be removed by surgery and may have spread.I've had radiation but have a tumor area not treated by it, and I've recovered from any side effects.I am 18 years old or older.My brain metastases are stable, and I haven't had seizures or worsening symptoms in the last 3 weeks.I have recovered from major surgery and it's been over 30 days since.My recent tests show my bone marrow, liver, and kidney functions are all within normal ranges.I have been cancer-free for at least two years, except for certain skin or early-stage cancers.I can provide a recent (less than 3 years old) tumor sample that wasn't treated with radiation.I am not pregnant or will use birth control during and 12 weeks after the study.I am fully active or can carry out light work.My lung cancer is advanced and cannot be removed by surgery.I've had TKI treatment for lung cancer but it either didn't work, caused severe side effects, or I couldn't tolerate it.My lung cancer cannot be removed by surgery and may have spread.I do not have any active infections, lung issues, uncontrolled high blood pressure, diabetes, seizures, or other serious health problems.I had basal cell carcinoma treated with the goal of curing it.My cancer started in a place other than my lungs and has spread.My brain metastases have been stable for less than 3 weeks.My lung cancer is not adenocarcinoma but another type.I haven't had heart failure, heart attack, stroke, or severe heart rhythm problems in the last 6 months.Your corrected QT interval is longer than 470 milliseconds.I switched to a TKI treatment without my cancer getting worse.You have HIV, hepatitis B, or hepatitis C.I have a cancer site that can be measured and hasn't been treated with radiation.I have not had a blood transfusion in the last 10 days.I haven't taken experimental drugs recently, except for TKIs with a proper washout period.I am on medication that is affected by certain body enzymes or transporters.You are expected to live for less than 3 months.
- Group 1: LP-300 in Combination with Pemetrexed and Carboplatin
- Group 2: Pemetrexed and Carboplatin (Standard of Care)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor taking on new participants presently?
"Data on clinicaltrials.gov indicates that recruitment for this medical trial is currently underway, with the initial posting being made on August 12th 2022 and most recent update occurring 16 days later."
How many individuals are being included as part of this research endeavor?
"Indeed, the information on clinicaltrials.gov confirms this trial is still recruiting candidates. It was first published on August 12th 2022 and revised most recently on September 16th 2022. The investigators are seeking 90 volunteers to participate in this study at two distinct sites."
Has the FDA authorized LP-300 as a treatment option?
"LP-300's safety rating stands at 2 due to the Phase 2 trial data, which has not yet shown efficacy but does offer evidence of its security."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Most responsive sites:
- Texas Oncology-Charles A. Sammons Cancer Center: < 24 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger